Fate Therapeutics (FATE) Tops Q2 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.30), $0.07 better than the analyst estimate of ($0.37).

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Macy's (M) Stock: Street Underestimates Earnings Pressure From Share Loss, Says Analyst
• Hooker Furniture (HOFT) Tops Q2 EPS by 16c, Misses on Revenue